{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T23:25:42Z","timestamp":1789601142797,"version":"build-2803163510"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,3,25]],"date-time":"2025-03-25T00:00:00Z","timestamp":1742860800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,3,25]],"date-time":"2025-03-25T00:00:00Z","timestamp":1742860800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardiovasc. Diabetol. \u2013 Endocrinol. Rep."],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Obesity is a chronic metabolic disease of global concern, often associated with Type 2 Diabetes Mellitus (T2DM). Global guidelines recommend holistic approach for T2DM management by addressing the associated comorbidities. Here, we have conducted a post-hoc evaluation of Liraglutide biosimilar Phase III trial on weight reduction and glycaemic benefits in Indian T2DM patients with obesity in comparison to reference liraglutide.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      We have conducted a post-hoc analysis of Liraglutide biosimilar Phase III trial on weight reduction in Indian T2DM patients with obesity in comparison to reference liraglutide. We evaluated weight reduction and HbA1c improvement in Indian T2DM patients (BMI\u2009&gt;\u200925\u00a0kg\/m\n                      <jats:sup>2<\/jats:sup>\n                      ) from baseline to week 24. Group A \u2013 Intervention arm: Liraglutide Biosimilar in T2DM patients with obesity Group B \u2013 Control arm: Reference Liraglutide in T2DM patients with obesity. Primary endpoint was mean change in body weight from baseline to week 24.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      179 T2DM patients (BMI\u2009&gt;\u200925 Kg\/m\n                      <jats:sup>2<\/jats:sup>\n                      and above) who satisfied the inclusion criteria, were included in this post-hoc analysis. The mean BMI of T2DM patients with obesity in Biosimilar Liraglutide arm was 29.8\u2009\u00b1\u20094.6\u00a0kg\/m\n                      <jats:sup>2<\/jats:sup>\n                      and that in the Reference Liraglutide arm it was 29.8\u2009\u00b1\u20094.8\u00a0kg\/m\n                      <jats:sup>2<\/jats:sup>\n                      . Significant mean weight reduction (Mean\u2009\u00b1\u2009SD) of 5.5\u2009\u00b1\u20091.2\u00a0kg (7.3\u2009\u00b1\u20091.7%) and 7.1\u2009\u00b1\u20092.6\u00a0kg (8.9\u2009\u00b1\u20091.7%) (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001) was demonstrated by both biosimilar liraglutide and reference liraglutide respectively. However, weight reduction was comparable across both the groups at week 24 (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.71). Likewise, glycaemic parameters (HbA1c, FPG and PPG) significantly improved in both the treatment arms (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001). However, they were comparable across the groups at week 24 with a p value of 0.89, 0.43 and 0.17 for HbA1c, FPG and PPG respectively.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Biosimilar Liraglutide at a dose of up to 1.8\u00a0mg was non-inferior to reference Liraglutide and resulted in significant weight reduction and glycemic control (HbA1c, FPG and PPG) in Indian T2DM patients with obesity.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s40842-025-00219-7","type":"journal-article","created":{"date-parts":[[2025,3,24]],"date-time":"2025-03-24T21:06:28Z","timestamp":1742850388000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Effect of liraglutide biosimilar vs. reference liraglutide on weight reduction in T2DM patients with obesity: post hoc analysis of phase III trial"],"prefix":"10.1186","volume":"11","author":[{"given":"Sujoy","family":"Ghosh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bipin","family":"Sethi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanjay","family":"Kalra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manash P.","family":"Baruah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abhishek","family":"Mane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanjay","family":"Choudhari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anup","family":"Petare","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mayur","family":"Jadhav","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saiprasad","family":"Patil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanmant","family":"Barkate","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,3,25]]},"reference":[{"key":"219_CR1","doi-asserted-by":"crossref","unstructured":"Okunogbe A, Nugent R, Spencer G, Ralston J, Wilding J. Economic impacts of overweight and obesity: current and future estimates for eight countries. BMJ Glob Heal. 2021 1;6(10):e006351.","DOI":"10.1136\/bmjgh-2021-006351"},{"key":"219_CR2","doi-asserted-by":"crossref","unstructured":"Raghavan S, Vassy JL, Ho Y, Song RJ, Gagnon DR, Cho K et al. Diabetes Mellitus\u2013Related All-Cause and Cardiovascular Mortality in a National Cohort of Adults. J Am Heart Assoc. 201919;8(4):e011295.","DOI":"10.1161\/JAHA.118.011295"},{"issue":"4","key":"219_CR3","doi-asserted-by":"publisher","first-page":"396","DOI":"10.4239\/wjd.v14.i4.396","volume":"14","author":"M Michaelidou","year":"2023","unstructured":"Michaelidou M, Pappachan JM, Jeeyavudeen MS. Management of diabesity: current concepts. World J Diabetes. 2023;14(4):396\u2013411.","journal-title":"World J Diabetes"},{"key":"219_CR4","doi-asserted-by":"crossref","unstructured":"Vasanthakumar J, Kambar S. Prevalence of obesity among type 2 diabetes mellitus patients in urban areas of Belagavi. Indian J Heal Sci Biomed Res Kleu. 2020;13(1).","DOI":"10.4103\/kleuhsj.kleuhsj_221_18"},{"issue":"7","key":"219_CR5","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1016\/S2213-8587(23)00119-5","volume":"11","author":"RM Anjana","year":"2023","unstructured":"Anjana RM, Unnikrishnan R, Deepa M, Pradeepa R, Tandon N, Das AK, et al. Metabolic non-communicable disease health report of India: the ICMR-INDIAB National cross-sectional study (ICMR-INDIAB-17). Lancet Diabetes Endocrinol. 2023;11(7):474\u201389.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"5","key":"219_CR6","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1016\/j.eprac.2023.02.001","volume":"29","author":"SL Samson","year":"2023","unstructured":"Samson SL, Vellanki P, Blonde L, Christofides EA, Galindo RJ, Hirsch IB, et al. American association of clinical endocrinology consensus statement: comprehensive type 2 diabetes management Algorithm \u2013 2023 update. Endocr Pract. 2023;29(5):305\u201340.","journal-title":"Endocr Pract"},{"key":"219_CR7","doi-asserted-by":"publisher","unstructured":"Summary Standards of Care in Diabetes\u20142024. Diabetes Care [Internet]. 2023. https:\/\/doi.org\/10.2337\/dc24-SREV. Accessed 12 Dec 2024.","DOI":"10.2337\/dc24-SREV"},{"issue":"7","key":"219_CR8","doi-asserted-by":"publisher","first-page":"1481","DOI":"10.2337\/dc10-2415","volume":"34","author":"RR Wing","year":"2011","unstructured":"Wing RR, Lang W, Wadden TA, Safford M, Knowler WC, Bertoni AG, et al. Benefits of modest weight loss in improving cardiovascular risk factors in overweight and obese individuals with type 2 diabetes. Diabetes Care. 2011;34(7):1481\u20136.","journal-title":"Diabetes Care"},{"issue":"6","key":"219_CR9","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1016\/S2213-8587(14)70057-9","volume":"2","author":"G Li","year":"2014","unstructured":"Li G, Zhang P, Wang J, An Y, Gong Q, Gregg EW, et al. Cardiovascular mortality, all-cause mortality, and diabetes incidence after lifestyle intervention for people with impaired glucose tolerance in the Da Qing diabetes prevention study: a 23-year follow-up study. Lancet Diabetes Endocrinol. 2014;2(6):474\u201380.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"3","key":"219_CR10","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1038\/oby.2000.32","volume":"8","author":"IL Mertens","year":"2000","unstructured":"Mertens IL, Van Gaal LF. Overweight, obesity, and blood pressure: the effects of modest weight reduction. Obes Res. 2000;8(3):270\u20138.","journal-title":"Obes Res"},{"issue":"4","key":"219_CR11","doi-asserted-by":"publisher","first-page":"250","DOI":"10.2337\/ds17-0044","volume":"30","author":"S Kahan","year":"2017","unstructured":"Kahan S, Fujioka K. Obesity pharmacotherapy in patients with type 2 diabetes. Diabetes Spectr. 2017;30(4):250\u20137.","journal-title":"Diabetes Spectr"},{"issue":"7","key":"219_CR12","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1001\/jama.2015.9676","volume":"314","author":"MJ Davies","year":"2015","unstructured":"Davies MJ, Bergenstal R, Bode B, Kushner RF, Lewin A, Skj\u00f8th TV, et al. Efficacy of liraglutide for weight loss among patients with type 2 diabetes: the SCALE diabetes randomized clinical trial. JAMA. 2015;314(7):687\u201399. A.","journal-title":"JAMA"},{"issue":"1","key":"219_CR13","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1056\/NEJMoa1411892","volume":"373","author":"X Pi-Sunyer","year":"2015","unstructured":"Pi-Sunyer X, Astrup A, Fujioka K, Greenway F, Halpern A, Krempf M, et al. A randomized, controlled trial of 3.0\u00a0mg of liraglutide in weight management. N Engl J Med. 2015;373(1):11\u201322.","journal-title":"N Engl J Med"},{"issue":"6","key":"219_CR14","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1159\/000478099","volume":"10","author":"C le Roux","year":"2017","unstructured":"le Roux C, Aroda V, Hemmingsson J, Cancino AP, Christensen R, Pi-Sunyer X. Comparison of efficacy and safety of liraglutide 3.0\u00a0mg in individuals with BMI above and below 35 kg\/m2: A Post-hoc analysis. Obes Facts. 2017;10(6):531\u201344.","journal-title":"Obes Facts"},{"issue":"1","key":"219_CR15","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1002\/osp4.84","volume":"3","author":"A Mehta","year":"2017","unstructured":"Mehta A, Marso SP, Neeland IJ. Liraglutide for weight management: a critical review of the evidence. Obes Sci Pract. 2017;3(1):3\u201314.","journal-title":"Obes Sci Pract"},{"key":"219_CR16","doi-asserted-by":"publisher","first-page":"111034","DOI":"10.1016\/j.diabres.2023.111034","volume":"207","author":"K Krishnan","year":"2024","unstructured":"Krishnan K, Raman S, Anand Moses CR, Rajesh RP, Gupta A, Mudaliar V, et al. Phase 3 efficacy and safety trial of proposed liraglutide biosimilar for reduction of glycosylated hemoglobin (HbA1c) in patients with type 2 diabetes mellitus. Diabetes Res Clin Pract. 2024;207:111034.","journal-title":"Diabetes Res Clin Pract"},{"issue":"6","key":"219_CR17","doi-asserted-by":"publisher","first-page":"1524","DOI":"10.1111\/jdi.13314","volume":"11","author":"C-A Chou","year":"2020","unstructured":"Chou C-A, Chuang S-F. Evaluation of the efficacy of low-dose liraglutide in weight control among Taiwanese non-diabetes patients. J Diabetes Investig. 2020;11(6):1524\u201331.","journal-title":"J Diabetes Investig"},{"issue":"5","key":"219_CR18","doi-asserted-by":"publisher","first-page":"e19835","DOI":"10.1371\/journal.pone.0019835","volume":"6","author":"D Wang","year":"2011","unstructured":"Wang D, Li Y, Lee SG, Wang L, Fan J, Zhang G, et al. Ethnic differences in body composition and obesity related risk factors: study in Chinese and white males living in China. PLoS ONE. 2011;6(5):e19835.","journal-title":"PLoS ONE"},{"issue":"3","key":"219_CR19","doi-asserted-by":"publisher","first-page":"247","DOI":"10.3803\/EnM.2019.34.3.247","volume":"34","author":"JA Sargeant","year":"2019","unstructured":"Sargeant JA, Henson J, King JA, Yates T, Khunti K, Davies MJ. A review of the effects of Glucagon-Like Peptide-1 receptor agonists and Sodium-Glucose cotransporter 2 inhibitors on lean body mass in humans. Endocrinol Metab. 2019;34(3):247\u201362.","journal-title":"Endocrinol Metab"},{"issue":"1","key":"219_CR20","doi-asserted-by":"publisher","first-page":"63","DOI":"10.17925\/EE.2022.18.1.63","volume":"18","author":"S Kalra","year":"2022","unstructured":"Kalra S, Mithal A, Zargar AH, Sethi B, Dharmalingam M, Ghosh S, et al. Indian phenotype characteristics among patients with type 2 diabetes mellitus: insights from a Non-interventional nationwide registry in India. TouchREVIEWS Endocrinol. 2022;18(1):63\u201370.","journal-title":"TouchREVIEWS Endocrinol"},{"issue":"6","key":"219_CR21","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1007\/s00125-020-05132-5","volume":"63","author":"KMV Narayan","year":"2020","unstructured":"Narayan KMV, Kanaya AM. Why are South Asians prone to type 2 diabetes? A hypothesis based on underexplored pathways. Diabetologia. 2020;63(6):1103\u20139.","journal-title":"Diabetologia"},{"issue":"8","key":"219_CR22","doi-asserted-by":"publisher","first-page":"1441","DOI":"10.2337\/dc14-2814","volume":"38","author":"RM Anjana","year":"2015","unstructured":"Anjana RM, Shanthi Rani CS, Deepa M, Pradeepa R, Sudha V, Divya Nair H, et al. Incidence of diabetes and prediabetes and predictors of progression among Asian Indians: 10-Year Follow-up of the Chennai urban rural epidemiology study (CURES). Diabetes Care. 2015;38(8):1441\u20138.","journal-title":"Diabetes Care"},{"issue":"3\u20134","key":"219_CR23","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1177\/0972753121998496","volume":"27","author":"R Nagarathna","year":"2020","unstructured":"Nagarathna R, Madhava M, Patil SS, Singh A, Perumal K, Ningombam G, et al. Cost of management of diabetes mellitus: A Pan India study. Ann Neurosci. 2020;27(3\u20134):190\u20132.","journal-title":"Ann Neurosci"}],"updated-by":[{"DOI":"10.1186\/s40842-025-00233-9","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2025,8,19]],"date-time":"2025-08-19T00:00:00Z","timestamp":1755561600000}}],"container-title":["Cardiovascular Diabetology \u2013 Endocrinology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40842-025-00219-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40842-025-00219-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40842-025-00219-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,6]],"date-time":"2025-09-06T07:36:19Z","timestamp":1757144179000},"score":1,"resource":{"primary":{"URL":"https:\/\/clindiabetesendo.biomedcentral.com\/articles\/10.1186\/s40842-025-00219-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,25]]},"references-count":23,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["219"],"URL":"https:\/\/doi.org\/10.1186\/s40842-025-00219-7","relation":{},"ISSN":["3059-4057"],"issn-type":[{"value":"3059-4057","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,25]]},"assertion":[{"value":"22 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 February 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 March 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 August 2025","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1186\/s40842-025-00233-9","URL":"https:\/\/doi.org\/10.1186\/s40842-025-00233-9","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human ethics and consent to participate declarations"}},{"value":"Abhishek Mane, Sanjay Choudhari, Anup Petare, Mayur Jadhav, Saiprasad Patil and Hanmant Barkate are employees of Glenmark Pharmaceuticals Ltd. While Glenmark was involved in aspects of manuscript support and data interpretation, all efforts were made to ensure the scientific integrity and objectivity of the study findings.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"6"}}